OXiGENE To Present Phase I Data Demonstrating Antitumor Activity Of OXi4503 In Patients With Acute Myeloid Leukemia And Myelodysplastic Syndromes

Published: Nov 18, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that data from a Phase 1 study of its dual-mechanism vascular disrupting agent OXi4503, demonstrating antitumor activity in patients with relapsed and refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), will be presented at the Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, December 7-10, 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news